Composition with lipase inhibitor and hydroxymethyl-glutaryl coenzyme A reductase inhibitor

A technology of hydroxymethylglutaryl coenzyme and lipase inhibitor, which is applied in the field of medicine

Inactive Publication Date: 2019-10-11
黄泳华
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] In the prior art, there is no technical teaching that the combination of orlistat and hydroxymethylglutaryl-CoA red

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition with lipase inhibitor and hydroxymethyl-glutaryl coenzyme A reductase inhibitor
  • Composition with lipase inhibitor and hydroxymethyl-glutaryl coenzyme A reductase inhibitor
  • Composition with lipase inhibitor and hydroxymethyl-glutaryl coenzyme A reductase inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1 Preparation of a composition composed of a lipase inhibitor and a hydroxymethylglutaryl-CoA reductase inhibitor

[0026] The lipase inhibitor and the hydroxymethylglutaryl coenzyme A reductase inhibitor in the ratio of specific substances are fully mixed to obtain the product.

[0027] The ratio of the amount of substance in the test example of the present invention and the embodiment includes: 0.008:1, 0.01:1, 0.013:1, 0.016:1, 0.02:1, 0.025:1, 0.032:1, 0.04:1, 0.05: 1, 0.063:1, 0.079:1, 0.1:1, 0.126:1, 0.158:1, 0.2:1, 0.251:1, 0.316:1, 0.398:1, 0.501:1, 0.631:1, 0.794:1, 1:1, 1.259:1, 1.585:1, 1.995:1, 2.512:1, 3.162:1, 3.981:1, 5.012:1, 6.31:1, 7.943:1, 10:1, 12.589:1, 15.849: 1, 19.953:1, 25.119:1, 31.623:1, 39.811:1, 50.119:1, 63.096:1, 79.433:1, 100:1, 125.893:1, 158.489:1.

Embodiment 2

[0081] Example 2 Preparation of Oral Solid Formulation Containing a Composition of Lipase Inhibitor and Hydroxymethylglutaryl-CoA Reductase Inhibitor

[0082] Prescription (1000 unit dose)

[0083]

[0084]

[0085]

[0086] Preparation

[0087] Take 50g of the composition and the prescription amount of auxiliary materials, and pass through a 100-mesh sieve. Get the composition, lactose, microcrystalline cellulose, crospovidone and starch and mix thoroughly; get the hypromellose of the prescription amount, and prepare a solution with a concentration of 10% based on hypromellose, and add lactic acid Adjust the pH to 3.0-4.0, add it to the above-mentioned mixture to make a soft material, granulate with a 16-mesh sieve, and dry at 80°C for 3-4 hours. Use a 16-mesh sieve to sieve the granules, add the prescribed amount of micropowder silica gel and magnesium stearate, mix well, fill the capsules, and obtain capsules;

[0088] Take 50g of the composition and the pres...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a composition with a lipase inhibitor and a hydroxymethyl-glutaryl coenzyme A reductase inhibitor, and a pharmaceutical preparation with the composition. Preferentially, the lipase inhibitor is one of orlistat and cetilistat, and the hydroxymethyl-glutaryl coenzyme A reductase inhibitor is one of atorvastatin, rosuvastatin, simvastatin, fluvastatin, pravastatin, lovastatin and pitavastatin or pharmaceutically-acceptable salt thereof. The composition can have the synergistic antibacterial effect and the synergistic histamine releasing inhibition effect, and therefore thetreatment effect and economic characteristics of bacterial infection-caused allergic disease patients can be improved.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a composition composed of a lipase inhibitor and a hydroxymethylglutaryl-CoA reductase inhibitor and a pharmaceutical preparation containing the composition. Background technique [0002] An allergic reaction is also known as anaphylaxis. It is tissue damage or physiological dysfunction caused by stimulation of the body by antigenic substances (such as bacteria, viruses, parasites, pollen, etc.). An abnormal or focal immune response. The so-called hypersensitivity reaction usually refers to type I hypersensitivity reaction, that is, immediate hypersensitivity reaction. The mechanism is that after the allergen enters the allergic person's body, specific antibodies are produced, and the latter binds to the surface of mast cells, making the body in an sensitized state. When exposed to the allergen for the first time, the mast cells degranulate and release various chem...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/06A61K31/365A61K31/366A61K31/505A61K31/405A61P31/04A61P37/08
CPCA61K31/365A61K31/366A61K31/405A61K31/505A61K45/06A61P31/04A61P37/08A61K2300/00Y02A50/30
Inventor 向飞孙伟光
Owner 黄泳华
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products